Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00643799 · ClinicalTrials.gov registry record · Phase 4

Safety and Efficacy of Celecoxib Versus Naproxen in the 6-month Treatment of Knee Osteoarthritis

A Phase 4 study of Osteoarthritis, Knee, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.

Completed
Registry status
Phase 4
Development phase
586
Enrollment target
20
Study locations

NCT00643799 is a Phase 4 study of Osteoarthritis, Knee that has completed, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 586 participants, roughly in line with the 574-participant average among 91 other Osteoarthritis, Knee trials with a reported enrollment target. The trial reports 20 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00643799, a Phase 4 study of Osteoarthritis, Knee, has completed, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.

COMPLETED
Registry status
Phase 4
Development phase
586 participants
Enrollment target
20
Study locations

Study Summary

To compare the safety and efficacy of celecoxib versus naproxen for the treatment of knee osteoarthritis

Conditions Studied

Osteoarthritis, Knee

Interventions

  • DRUG Placebo
  • DRUG Celecoxib
  • DRUG Naproxen

Study Locations (20)

Florida

  • Pfizer Investigational Site - Clearwater
  • Pfizer Investigational Site - DeLand
  • Pfizer Investigational Site - Jacksonville
  • Pfizer Investigational Site - Miami
  • Pfizer Investigational Site - Ocala
  • Pfizer Investigational Site - Orlando
  • Pfizer Investigational Site - Pembroke Pines
  • Pfizer Investigational Site - Tampa
  • Pfizer Investigational Site - Zephyrhills

California

  • Pfizer Investigational Site - Buena Park
  • Pfizer Investigational Site - Paramount
  • Pfizer Investigational Site - Rancho Mirage
  • Pfizer Investigational Site - San Diego
  • Pfizer Investigational Site - San Diego

Arizona

  • Pfizer Investigational Site - Phoenix
  • Pfizer Investigational Site - Tempe

Alabama

  • Pfizer Investigational Site - Montgomery

Colorado

  • Pfizer Investigational Site - Denver

District of Columbia

  • Pfizer Investigational Site - Washington D.C.

Illinois

  • Pfizer Investigational Site - Rockford

Trial Details

FieldValue
Enrollment Target 586 participants
Start Date 2004-03
Est. Completion 2005-01
Phase Phase 4

Sponsor

Pfizer's Upjohn has merged with Mylan to form Viatris

158 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00643799

The ClinicalTrials.gov registry entry for NCT00643799 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 586 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 574-participant average among 91 other Osteoarthritis, Knee trials with a reported enrollment target. The listed sponsor is Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Osteoarthritis, Knee appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT00643799 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Florida, California, Arizona.

Frequently Asked Questions

What is clinical trial NCT00643799 about?

NCT00643799 is a clinical study titled "Safety and Efficacy of Celecoxib Versus Naproxen in the 6-month Treatment of Knee Osteoarthritis". To compare the safety and efficacy of celecoxib versus naproxen for the treatment of knee osteoarthritis

What is the current status of trial NCT00643799?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 586 participants. The study started on 2004-03. Estimated completion is 2005-01.

What conditions does trial NCT00643799 study?

This clinical trial studies the following conditions: Osteoarthritis, Knee.

What interventions are being tested in trial NCT00643799?

The interventions under investigation include: Placebo (DRUG), Celecoxib (DRUG), Naproxen (DRUG).

Who is sponsoring clinical trial NCT00643799?

This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00643799 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Osteoarthritis, Knee

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Osteoarthritis, Knee

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.